0
0
A landmark study led by the University of Edinburgh has for the first time demonstrated clear, consistent differences in the blood of individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) compared to healthy controls. The research, published in EMBO Molecular Medicine, is the largest biological investigation of ME/CFS to date and analyzed over 3,000 blood-based biomarkers from 1,455 ME/CFS patients and 131,000 healthy individuals using data from the UK Biobank.
Key Findings and Implications
The study identified significant blood differences associated with chronic inflammation, insulin resistance, and liver disease in ME/CFS patients. Notably, these differences were mostly unaffected by patients’ activity levels, countering previous suggestions that biological changes might simply result from reduced physical activity. Advanced statistical models and machine learning techniques were used to account for variables such as age, sex, and activity, making the findings robust and reproducible.
Among the most striking results were 116 significant biomarker differences found in both men and women, with the most pronounced changes in patients reporting post-exertional malaise—a hallmark symptom of ME/CFS characterized by a dramatic worsening of symptoms after minor physical or mental exertion. Post-exertional malaise is often described as a delayed and disproportionate response to activity, with symptoms that can last days or longer.
A Path Toward Reliable Diagnosis
Currently, there is no diagnostic test or cure for ME/CFS, which remains a complex, poorly understood condition affecting multiple body systems and causing debilitating fatigue, pain, brain fog, and other symptoms that do not improve with rest. The discovery of consistent blood biomarkers across large patient groups supports the development of a blood test for ME/CFS, offering hope for more reliable diagnosis and future research into targeted treatments.
Professor Chris Ponting of the MRC Human Genetics Unit at the University of Edinburgh emphasized the significance of the findings: “For so long, people with ME/CFS have been told it’s all in their head. It’s not: we see people’s ME/CFS in their blood.” The study also dispels misconceptions that ME/CFS is caused by deconditioning or exercise intolerance, as the blood differences persisted even after accounting for activity levels.
Future Directions
The research team replicated their findings using data from the United States, further strengthening the reliability of the identified biomarkers. The collaboration between genetics, mathematics, and informatics experts highlights the importance of interdisciplinary approaches in tackling complex diseases like ME/CFS.
While the study marks a major step forward, more research is needed to fully understand the underlying causes of ME/CFS and to translate these biomarker discoveries into clinical practice.
Disclaimer:
This news article is based on the study published in EMBO Molecular Medicine and reported by Medical Xpress. It is intended for informational purposes only and does not constitute medical advice. Readers are encouraged to consult healthcare professionals for diagnosis and treatment options related to ME/CFS or any other medical condition. The original research can be found in the cited journal article and news source.
